Cantor Fitzgerald raised the firm’s price target on Exagen (XGN) to $10 from $7 and keeps an Overweight rating on the shares. The company reported strong Q2 operating results and raised the top-end of FY25 revenue guidance, the analyst tells investors in a research note. Cantor remains excited about Exagen as the company continues to roll out new biomarkers that stand to improve sensitivity, which should result in incremental adoption in addition to being accretive to average selling price.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN:
- Exagen price target raised to $11 from $8 at Canaccord
- Exagen’s Strong Q2 Performance and Growth Strategy Justify Buy Rating
- KeyBanc upgrades Exagen on improved revenue visibility
- Exagen Inc. Reports Record Q2 2025 Revenue
- Exagen’s Promising Financial Trajectory and Raised Price Target Amid Strong Performance and Strategic Growth Initiatives